At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Zanubrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib for Refractory Mantle Cell Lymphoma and Relapsed Mantle Cell Lymphoma. Completed, enrolled 86 participants across 13 sites.
Detailed Summary
The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedJul 2017
Primary CompletionFeb 2019
Study CompletionSep 2020
TodayJul 2026
First PostedJul 2, 2017
Enrollment StartMar 2, 2017
Primary CompletionFeb 15, 2019
Study CompletionSep 8, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9 years ago
Interventions
Zanubrutinibdrug
Administered as specified in the treatment arm.